Assertio Therapeutics (ASRT) Tops Q2 EPS by 1c

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.25, $0.01 better than the analyst estimate of $0.24. Revenue for the quarter came in at $59.3 million versus the consensus estimate of $59.05 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• NHC acquires 35 facilities from NHI for $560 million
• American Eagle Outfitters names new CFO, reaffirms 2026 guidance